Krempa David
Krempa David, CBO, reported a transaction classified as exercise at Eton Pharmaceuticals, Inc. involving 12476.000000 shares for an estimated $17092.12. Reported holdings after the transaction were 37725.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
- Trade date
- May 27, 2026
- Filing date
- May 27, 2026
How reported position traded is calculated
Calculated only for code-P purchases and code-S sales.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
ETON price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- exercise Code M
- Identifier
- 0001437749-26-018628 Common Stock
- Transaction date
- May 27, 2026 Filed May 27, 2026, 10:28 PM · 0d delay
- Shares
- 12,476 sh $1.37 per share
- Estimated value
- $17.0k Computed from shares × price
- Holdings after
- 37,725 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
+10 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - timely_filing+4 points
reporting_delay_days = 0
Filing reported within two business days of the transaction.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
Chief Business Officer
- F1
The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at…
- F2
The shares were sold in multiple trades at prices ranging from $33.68 to $34.66. The price reported above reflects the weighted average sales price.
- F3
The shares were sold in multiple trades at prices ranging from $31.27 to $32.16. The price reported above reflects the weighted average sales price.
- F4
The shares subject to the option vested in 48 equal monthly installments from the date of grant (3-12-2020) until fully vested.
- F5
The shares were sold in multiple trades at prices ranging from $31.25 to $31.825. The price reported above reflects the weighted average sales price.
- F6
The shares subject to the option vested annually from the date of grant (11-10-2017) in four equal installments.
- F7
The shares were sold in multiple trades at prices ranging from $32.67 to $33.65. The price reported above reflects the weighted average sales price.
- F8
The shares subject to option vested annually from the date of grant (8-7-2017) in four equal installments.
0 other transactions
0 recent txs